| Summary: | 碩士 === 國立臺灣大學 === 醫學工程學研究所 === 106 === Osteoarthritis (OA) is a chronic joint injury disease. Its progressive course leads to cartilage fibrosis due to tissue nature to not easy to recover after damage. Present aids for OA are primarily focuses for alleviating the symptoms of the disease rather than prevent or cure the disease process. Therefore, development of new therapeutic strategies and biomaterials are always on-demand for OA regenerative medicine. It has been reported that resveratrol can inhibit the inflammatory rate of OA, but bioavailability of resveratrol is still controversy. In order to improve this point, the polysaccharide isolated from Bletilla striata (BSP) is added. Recent studies found that BSP has antioxidative and anti-inflammatory properties, which can strengthen the role of resveratrol to provide an anti-inflammatory effect.
In this study, a mixture of 50 μM resveratrol and 100 µg/mL BSP (RB) was tested for cytotoxicity potential, then applied to an experimental model of OA-like chondrocytes induced by lipopolysaccharide (LPS) thus evaluated its ECM activity and gene expression. The experimental results showed that the BSP have the correct functional groups, and RB has been proved to have good biocompatibility through the WST-1 test and LIVE/DEAD staining. ICC type II collagen, Alcian blue staining, and gene expression evaluation showed that RB able to maintained the expression of ECM and inflammatory-related genes caused by LPS-stimulated chondrocyte, could be effectively reduced. To conclude, BSP can significantly maintain the expression of extracellular matrix, while resveratrol can reduce the symptoms of inflammation, and the mixture of BSP and resveratrol has the advantages of both, so it has great potentials for OA early treatment and prevention.
|
|---|
